What Could Nuvectis Pharma's(NASDAQ:NVCT) In-Licensing Deal Mean for Its Complement and Oncology Pipeline?

Sonal Goyal

05 November 2026 12:39 PM AEDT

What Could Nuvectis Pharma's(NASDAQ:NVCT) In-Licensing Deal Mean for Its Complement and Oncology Pipeline?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• Nuvectis in-licensed ex-China rights to ciprocopan (NXP100) and NXP200 from Haisco Pharmaceutical Group, transforming the company into a late-stage clinical development firm.

• Ciprocopan received its first global approval in China in July 2026 for the treatment of PNH patients previously untreated with complement inhibitors.

• FDA discussions regarding the U.S. regulatory pathway for ciprocopan in PNH are underway, with an update expected before year-end 2026.

• Cash position stood at approximately $140 million, expected to fund operations into the second half of 2029.

Nuvectis Pharma, Inc.(NASDAQ:NVCT), a clinical-stage biopharmaceutical company focused on complement-related conditions and oncology, reported its third-quarter 2026 financial results alongside a series of developments that have reshaped its pipeline and strategic direction. The company's in-licensing deal with Haisco Pharmaceutical Group for two late-stage drug candidates has positioned Nuvectis as a potential contender in the complement inhibitor space, while its cash reserves provide a multi-year operational runway.

A Transformative In-Licensing Transaction

The quarter's defining event was the completion of an in-licensing agreement with Haisco Pharmaceutical Group for the ex-China rights to ciprocopan (NXP100), a Complement Factor B inhibitor, and NXP200, a paradox-breaker BRAF inhibitor. The deal, combined with a follow-on public offering anchored by healthcare-focused investors, fundamentally altered Nuvectis' development profile.

Ciprocopan achieved its first regulatory approval worldwide in July 2026, when Chinese authorities cleared it for patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not been previously treated with complement inhibitors. A second Marketing application in China for previously treated PNH patients is under review, with approval anticipated in Q1 2027. Additional clinical programs in China include a Phase 3 study in IgA nephropathy and a Phase 2 trial in lupus nephritis.

U.S. Regulatory Path Takes Shape

Nuvectis is currently in discussions with the U.S. FDA about whether the clinical data supporting ciprocopan's approval in China could form the basis for a marketing application in the United States. An update on these discussions is expected before the end of 2026. The company also plans to submit a U.S. Investigational New Drug (IND) application for ciprocopan in an indication beyond PNH by year-end.

Chairman and CEO Ron Bentsur highlighted ciprocopan's potential dosing advantage, noting its once-daily oral formulation compared to injectable treatments and Fabhalta, another oral Complement Factor B inhibitor that requires twice-daily dosing. Phase 3 data from a head-to-head study conducted in China comparing ciprocopan to eculizumab (Soliris) in treatment-naive PNH patients demonstrated an efficacy advantage for ciprocopan.

Oncology Candidate Shows Early Promise

On the oncology side, expanded Phase 1b results for NXP200 in patients with BRAF V600-mutated recurrent or progressive glioma were presented at the 2026 ESMO Congress. The data showed durable responses, including complete responses, with activity also observed in patients who had previously received a BRAF inhibitor. NXP200 received Breakthrough Therapy Designation from China's Center for Drug Evaluation for this indication. Nuvectis expects to submit a U.S. IND for NXP200 by year-end.

Financial Position Provides Extended Runway

Nuvectis ended Q3 2026 with approximately $140 million in cash, which the company described as the highest financial position in its history. This funding is expected to support operations into the second half of 2029, extending beyond multiple anticipated clinical and regulatory milestones.

Looking Ahead

Nuvectis Pharma has rapidly evolved from a small-cap oncology company into a multi-asset, late-stage development firm with programs spanning hematology, nephrology, and oncology. The outcome of FDA discussions on ciprocopan's U.S. regulatory path will be a critical near-term catalyst, while Phase 3 results and additional data readouts across both NXP100 and NXP200 could further define the company's trajectory into 2027.

FAQs

Q: What is ciprocopan (NXP100)?

A: Ciprocopan is an oral, once-daily Complement Factor B inhibitor in-licensed by Nuvectis from Haisco Pharmaceutical Group. It was approved in China in July 2026 for treating PNH.

Q: When will Nuvectis update on FDA discussions for ciprocopan?

A: The company expects to provide an update on its U.S. FDA discussions regarding ciprocopan's regulatory path before the end of 2026.

Q: What is NXP200?

A: NXP200 is a second-generation, paradox-breaker BRAF inhibitor being developed for BRAF V600-mutated glioma. It received Breakthrough Therapy Designation in China and is advancing toward a U.S. IND submission.

Q: How long is Nuvectis' cash runway?

A: With approximately $140 million in cash at the end of Q3 2026, Nuvectis expects to fund operations into the second half of 2029.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.